EAST HANOVER, N.J., Jan. 16, 2018 /PRNewswire/ — Novartis announced today results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx® (secukinumab) compared to Stelara® (ustekinumab) in delivering clear and almost clear skin in adults with moderate to severe…
